Partial Onset Seizures
Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy.
Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy
Keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
Primary Generalized Tonic-Clonic Seizures
Keppra is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.
Keppra Dosage and Administration
Important Administration Instructions
Keppra is given orally with or without food. The Keppra dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.
Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.
When using the oral solution, in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).
Keppra tablets should be swallowed whole. Keppra tablets should not be chewed or crushed.
Partial Onset Seizures
Adults 16 Years And Older
In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.
Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
Pediatric Patients
1 Month To < 6 Months
Treatment should be initiated with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.
6 Months To <4 Years:
Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.
4 Years To < 16 Years
Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.
For Keppra tablet dosing in pediatric patients weighing 20 to 40 kg, treatment should be initiated with a daily dose of 500 mg given as twice daily dosing (250 mg twice daily). The daily dose should be increased every 2 weeks by increments of 500 mg to a maximum recommended daily dose of 1500 mg (750 mg twice daily).
For Keppra tablet dosing in pediatric patients weighing more than 40 kg, treatment should be initiated with a daily dose of 1000 mg/day given as twice daily dosing (500 mg twice daily). The daily dose should be increased every 2 weeks by increments of 1000 mg/day to a maximum recommended daily dose of 3000 mg (1500 mg twice daily).
Keppra Oral Solution Weight-Based Dosing Calculation For Pediatric Patients
The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:
| Total daily dose (mL/day) = | Daily dose (mg/kg/day) × patient weight (kg) |
| ----------------------------------------- | |
| 100 mg/mL | |
Myoclonic Seizures In Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy
Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
Primary Generalized Tonic-Clonic Seizures
Adults 16 Years And Older
Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.
Pediatric Patients Ages 6 To <16 Years
Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.
Adult Patients With Impaired Renal Function
Keppra dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:
| CLcr= | [140-age (years)] × weight (kg) | |
| ----------------------------------------- (× 0.85 for female patients) | ||
| 72 × serum creatinine (mg/dL) | ||
Then CLcr is adjusted for body surface area (BSA) as follows:
| CLcr (mL/min/1.73m2)= | CLcr (mL/min) | |
| ---------------------------- × 1.73 | ||
| BSA subject (m2) | ||
| |||
| Group | Creatinine Clearance (mL/min/1.73m2) | Dosage (mg) | Frequency |
| Normal | > 80 | 500 to 1,500 | Every 12 hours |
| Mild | 50 – 80 | 500 to 1,000 | Every 12 hours |
| Moderate | 30 – 50 | 250 to 750 | Every 12 hours |
| Severe | < 30 | 250 to 500 | Every 12 hours |
| ESRD patients using dialysis | ---- | 500 to 1,000* | Every 24 hours* |
Dosage Forms and Strengths
Keppra 250 mg tablets are blue, oblong-shaped, scored, film-coated, and debossed with "ucb 250" on one side.
Keppra 500 mg tablets are yellow, oblong-shaped, scored, film-coated, and debossed with "ucb 500" on one side.
Keppra 750 mg tablets are orange, oblong-shaped, scored, film-coated, and debossed with "ucb 750" on one side.
Keppra 1000 mg tablets are white, oblong-shaped, scored, film-coated, and debossed with "ucb 1000" on one side.
Keppra 100 mg/mL oral solution is a clear, colorless, grape-flavored liquid.
Contraindications
None.
Warnings and Precautions
Psychiatric Reactions
In some patients Keppra causes behavioral abnormalities. The incidences of behavioral abnormalities in the myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult and pediatric partial onset seizure studies.
A total of 13.3% of adult Keppra-treated patients and 37.6% of pediatric Keppra-treated patients (4 to 16 years of age) compared to 6.2% and 18.6% of adult and pediatric placebo patients respectively, experienced non-psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder). A randomized double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of Keppra as adjunctive therapy in pediatric patients (4 to 16 years of age). The results from an exploratory analysis indicated a worsening in Keppra-treated patients on aggressive behavior (one of eight behavior dimensions) as measured in a standardized and systematic way using a validated instrument, the Achenbach Child Behavior Checklist (CBCL/6-18).
In pediatric patients 1 month to < 4 years of age, irritability was reported in 11.7% of the Keppra-treated patients compared to 0% of placebo patients.
A total of 1.7% of adult Keppra-treated patients discontinued treatment due to behavioral adverse events, compared to 0.2% of placebo patients. The treatment dose was reduced in 0.8% of adult Keppra-treated patients and in 0.5% of placebo patients. Overall, 10.9% of Keppra-treated pediatric patients experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6.2% of placebo patients.
One percent of adult Keppra-treated patients, 2% of children 4 to 16 years of age, and 17% of children 1 month to <4 years of age experienced psychotic symptoms, compared to 0.2%, 2%, and 5% respectively, in the placebo patients. In the controlled study that assessed the neurocognitive and behavioral effects of Keppra in pediatric patients 4 to 16 years of age, 1 (1.6%) Keppra-treated patient experienced paranoia compared to no placebo patients. There were 2 (3.1%) Keppra-treated patients that experienced confusional state compared to no placebo patients [see Use in Specific Populations (8.4)].
Two (0.3%) adult Keppra-treated patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation. There was no difference between drug and placebo-treated patients in the incidence of the pediatric patients who discontinued treatment due to psychotic and non-psychotic adverse reactions.
The above psychiatric signs symptoms should be monitored.
Suicidal Behavior and Ideation
Antiepileptic drugs (AEDs), including Keppra, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs.
| Table 2 | Risk by indication for antiepileptic drugs in the pooled analysis | |||
|---|---|---|---|---|
| Indication | Placebo Patients with Events Per 1000 Patients | Drug Patients with Events Per 1000 Patients | Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients | Risk Difference: Additional Drug Patients with Events Per 1000 Patients |
| Epilepsy | 1.0 | 3.4 | 3.5 | 2.4 |
| Psychiatric | 5.7 | 8.5 | 1.5 | 2.9 |
| Other | 1.0 | 1.8 | 1.9 | 0.9 |
| Total | 2.4 | 4.3 | 1.8 | 1.9 |
The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.
Anyone considering prescribing Keppra or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
Somnolence and Fatigue
In some patients, Keppra causes somnolence and fatigue. The incidences of somnolence and fatigue provided below are from controlled adult partial onset seizure studies. In general, the incidences of somnolence and fatigue in the pediatric partial onset seizure studies, and in pediatric and adult myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial onset seizure studies.
In controlled trials of adult patients with epilepsy experiencing partial onset seizures, 14.8% of Keppra-treated patients reported somnolence, compared to 8.4% of placebo patients. There was no clear dose response up to 3000 mg/day. In a study where there was no titration, about 45% of patients receiving 4000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of the treated patients, compared to 0% in the placebo group. About 3% of Keppra-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo patients. In 1.4% of treated patients and in 0.9% of placebo patients the dose was reduced, while 0.3% of the treated patients were hospitalized due to somnolence.
In controlled trials of adult patients with epilepsy experiencing partial onset seizures, 14.7% of Keppra-treated patients reported asthenia, compared to 9.1% of placebo patients. Treatment was discontinued due to asthenia in 0.8% of treated patients as compared to 0.5% of placebo patients. In 0.5% of treated patients and in 0.2% of placebo patients the dose was reduced due to asthenia.
Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment.
Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on Keppra to gauge whether it adversely affects their ability to drive or operate machinery.
Serious Dermatological Reactions
Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in both children and adults treated with levetiracetam. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment. Recurrence of the serious skin reactions following rechallenge with levetiracetam has also been reported. Keppra should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.
Coordination Difficulties
Coordination difficulties were only observed in the adult partial onset seizure studies. A total of 3.4% of adult Keppra-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or incoordination) compared to 1.6% of placebo patients. A total of 0.4% of patients in controlled trials discontinued Keppra treatment due to ataxia, compared to 0% of placebo patients. In 0.7% of treated patients and in 0.2% of placebo patients the dose was reduced due to coordination difficulties, while one of the treated patients was hospitalized due to worsening of pre-existing ataxia. These events occurred most frequently within the first 4 weeks of treatment.
Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on Keppra to gauge whether it could adversely affect their ability to drive or operate machinery.
Withdrawal Seizures
Antiepileptic drugs, including Keppra, should be withdrawn gradually to minimize the potential of increased seizure frequency.
Hematologic Abnormalities
Partial Onset Seizures
Adults
Minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 x 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in Keppra-treated patients in controlled trials.
A total of 3.2% of treated and 1.8% of placebo patients had at least one possibly significant (≤2.8 × 109/L) decreased WBC, and 2.4% of treated and 1.4% of placebo patients had at least one possibly significant (≤1.0 × 109/L) decreased neutrophil count. Of the treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.
Pediatric Patients 4 Years To < 16 Years
Statistically significant decreases in WBC and neutrophil counts were seen in Keppra-treated patients as compared to placebo. The mean decreases from baseline in the Keppra-treated group were -0.4 × 109/L and -0.3 × 109/L, respectively, whereas there were small increases in the placebo group. Mean relative lymphocyte counts increased by 1.7% in Keppra-treated patients, compared to a decrease of 4% in placebo patients (statistically significant).
In the controlled trial, more Keppra-treated patients had a possibly clinically significant abnormally low WBC value (3.0% Keppra-treated versus 0% placebo), however, there was no apparent difference between treatment groups with respect to neutrophil count (5.0% Keppra-treated versus 4.2% placebo). No patient was discontinued secondary to low WBC or neutrophil counts.
In the controlled cognitive and neuropsychological safety study, two subjects (6.1%) in the placebo group and 5 subjects (8.6%) in the Keppra-treated group had high eosinophil count values that were possibly clinically significant (≥10% or ≥0.7×109/L).
Juvenile Myoclonic Epilepsy
Although there were no obvious hematologic abnormalities observed in patients with JME, the limited number of patients makes any conclusion tentative. The data from the partial seizure patients should be considered to be relevant for JME patients.
Blood Pressure Increases
In a randomized, placebo-controlled study in patients aged 1 month to <4 years of age, a significantly higher risk of at least one measured increase in diastolic blood pressure was observed in the Keppra-treated patients (17%) compared to the placebo-treated patients (2%). There was no overall difference in mean diastolic blood pressure between the treatment groups. This disparity between the Keppra and placebo treatment groups was not observed in the studies of older children or in adults.
Seizure Control During Pregnancy
Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.
Adverse Reactions
The following adverse reactions are discussed in more details in other sections of labeling:
- Psychiatric Symptoms [see Warnings and Precautions (5.1)]
- Suicidal Behavior and Ideation [see Warnings and Precautions (5.2)]
- Somnolence and Fatigue [see Warnings and Precautions (5.3)]
- Serious Dermatological Reactions [see Warnings and Precautions (5.4)]
- Coordination Difficulties [see Warnings and Precautions (5.5)]
- Withdrawal Seizures [see Warnings and Precautions (5.6)]
- Hematologic Abnormalities [see Warnings and Precautions (5.7)]
- Blood Pressure Increases [see Warnings and Precautions (5.8)]
- Seizure Control During Pregnancy [see Warnings and Precautions (5.9)]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The prescriber should be aware that the adverse reaction incidence figures in the following tables, obtained when Keppra was added to concurrent AED therapy, cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical trials. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.
Partial Onset Seizures
Adults
In controlled clinical studies in adults with partial onset seizures, the most frequently reported adverse reactions in patients receiving Keppra in combination with other AEDs were somnolence, asthenia, infection and dizziness. Of the most frequently reported adverse reactions in adults experiencing partial onset seizures, asthenia, somnolence and dizziness appeared to occur predominantly during the first 4 weeks of treatment with Keppra.
Table 3 lists adverse reactions that occurred in at least 1% of adult epilepsy patients treated with Keppra participating in placebo-controlled studies and were numerically more common than in patients treated with placebo. In these studies, either Keppra or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.
| Body System/ Adverse Reaction | Keppra (N=769) % | Placebo (N=439) % |
|---|---|---|
| Body as a Whole | ||
| Asthenia | 15 | 9 |
| Headache | 14 | 13 |
| Infection | 13 | 8 |
| Pain | 7 | 6 |
| Digestive System | ||
| Anorexia | 3 | 2 |
| Nervous System | ||
| Somnolence | 15 | 8 |
| Dizziness | 9 | 4 |
| Depression | 4 | 2 |
| Nervousness | 4 | 2 |
| Ataxia | 3 | 1 |
| Vertigo | 3 | 1 |
| Amnesia | 2 | 1 |
| Anxiety | 2 | 1 |
| Hostility | 2 | 1 |
| Paresthesia | 2 | 1 |
| Emotional Lability | 2 | 0 |
| Respiratory System | ||
| Pharyngitis | 6 | 4 |
| Rhinitis | 4 | 3 |
| Cough Increased | 2 | 1 |
| Sinusitis | 2 | 1 |
| Special Senses | ||
| Diplopia | 2 | 1 |
In controlled adult clinical studies, 15% of patients receiving Keppra and 12% receiving placebo either discontinued or had a dose reduction as a result of an adverse event. Table 4 lists the most common (>1%) adverse reactions that resulted in discontinuation or dose reduction and that occurred more frequently in Keppra-treated patients than in placebo-treated patients.
| Adverse Reaction | Keppra (N=769) % | Placebo (N=439) % |
|---|---|---|
| Dizziness | 1 | 0 |
| Somnolence | 4 | 2 |
Pediatric Patients 4 Years To <16 Years
The adverse reaction data presented below was obtained from a pooled analysis of two controlled pediatric clinical studies in children 4 to 16 years of age with partial onset seizures. The adverse reactions most frequently reported with the use of Keppra in combination with other AEDs, not seen at an equivalent frequency among placebo-treated patients, were fatigue, aggression, nasal congestion, decreased appetite, and irritability.
Table 5 lists adverse reactions from the pooled pediatric controlled studies (4 to 16 years of age) that occurred in at least 2% of pediatric Keppra-treated patients and were numerically more common than in pediatric patients treated with placebo. In these studies, either Keppra or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.
| Body System/ Adverse Reaction | Keppra (N=165) % | Placebo (N=131) % |
|---|---|---|
| Ear and Labyrinth Disorders | ||
| Ear Pain | 2 | 1 |
| Eye Disorders | ||
| Conjunctivitis | 2 | 0 |
| Gastrointestinal Disorders | ||
| Vomiting | 15 | 12 |
| Abdominal Pain Upper | 9 | 8 |
| Diarrhea | 6 | 5 |
| Constipation | 3 | 1 |
| General Disorders and Administration Site Conditions | ||
| Fatigue | 11 | 5 |
| Infections and Infestations | ||
| Nasopharyngitis | 15 | 12 |
| Influenza | 3 | 1 |
| Gastroenteritis | 2 | 0 |
| Rhinitis | 2 | 0 |
| Injury, Poisoning and Procedural Complications | ||
| Head Injury | 4 | 0 |
| Contusion | 3 | 1 |
| Fall | 3 | 2 |
| Joint Sprain | 2 | 1 |
| Metabolism and Nutrition Disorders | ||
| Decreased Appetite | 8 | 2 |
| Anorexia | 4 | 3 |
| Musculoskeletal and Connective Tissue Disorders | ||
| Arthralgia | 2 | 0 |
| Neck Pain | 2 | 1 |
| Nervous System | ||
| Headache | 19 | 15 |
| Somnolence | 13 | 9 |
| Dizziness | 7 | 5 |
| Lethargy | 6 | 2 |
| Sedation | 2 | 1 |
| Psychiatric Disorders | ||
| Aggression | 10 | 5 |
| Abnormal Behavior | 7 | 4 |
| Irritability | 7 | 1 |
| Insomnia | 5 | 3 |
| Agitation | 4 | 1 |
| Depression | 3 | 1 |
| Mood Altered | 3 | 1 |
| Affect Lability | 2 | 1 |
| Anxiety | 2 | 1 |
| Confusional State | 2 | 0 |
| Mood Swings | 2 | 1 |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Cough | 9 | 5 |
| Nasal Congestion | 9 | 2 |
| Pharyngolaryngeal Pain | 7 | 4 |
In the well controlled pooled pediatric clinical studies in patients 4-16 years of age, 7% of patients receiving Keppra and 9% receiving placebo discontinued as a result of an adverse event.
Pediatric Patients 1 Month To < 4 Years
In the 7-day, controlled pediatric clinical study in children 1 month to less than 4 years of age with partial onset seizures, the adverse reactions most frequently reported with the use of Keppra in combination with other AEDs, not seen at an equivalent frequency among placebo-treated patients, were somnolence and irritability. Because of the shorter exposure period, incidences of adverse reactions are expected to be lower then in other pediatric studies in older patients. Therefore, other controlled pediatric data, presented above, should also be considered to apply to this age group.
Table 6 lists adverse reactions that occurred in at least 5% of pediatric epilepsy patients (ages 1 month to < 4 years) treated with Keppra participating in the placebo-controlled study and were numerically more common than in patients treated with placebo. In this study, either Keppra or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.
| Body System/ Adverse Reaction | Keppra (N=60) % | Placebo (N=56) % |
|---|---|---|
| Nervous System | ||
| Somnolence | 13 | 2 |
| Psychiatric Disorders | ||
| Irritability | 12 | 0 |
In the 7-day controlled pediatric clinical study in patients 1 month to < 4 years of age, 3% of patients receiving Keppra and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse event. There was no adverse event that resulted in discontinuation for more than one patient.
Myoclonic Seizures
Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies. The adverse reaction pattern for patients with JME is expected to be essentially the same as for patients with partial seizures.
In the well-controlled clinical study that included both adolescent (12 to 16 years of age) and adult patients with myoclonic seizures, the most frequently reported adverse reactions in patients using Keppra in combination with other AEDs, not seen at an equivalent frequency among placebo-treated patients, were somnolence, neck pain, and pharyngitis.
Table 7 lists adverse reactions that occurred in at least 5% of juvenile myoclonic epilepsy patients experiencing myoclonic seizures treated with Keppra and were numerically more common than in patients treated with placebo. In this study, either Keppra or placebo was added to concurrent AED therapy. Adverse reactions were usually mild to moderate in intensity.
| Body System/ Adverse Reaction | Keppra (N=60) % | Placebo |
|---|
No comments:
Post a Comment